Smolenski C, Muff S, Smolenski-Kautz S
Curr Med Res Opin. 1981;7(6):374-83.
A double-blind trial with two parallel groups was carried out to compare the antispastic effect and tolerability of a new muscle relaxant, tizanidine (DS 103-282), with those of baclofen in the treatment of spasticity due to multiple sclerosis. Twenty-one hospitalized patients with stable spasticity participated in the 6-week trial. Eleven received tizanidine and 10 baclofen in gradually increasing daily doses. The optimal daily dose of tizanidine was between 8 and 36 mg and that of baclofen between 10 and 80 mg. Overall spastic state, spasms and clonus were similarly improved with both medications. In contrast, muscle strength, bladder function and the activities of daily living were more improved on tizanidine than on baclofen. Tiredness was the most frequent side-effect on tizanidine and muscle weakness on baclofen. The laboratory tests did not show any pathological changes with either medication. According to these results, tizanidine provides a new therapeutic alternative in the treatment of spasticity.
进行了一项双盲试验，设有两个平行组，以比较新型肌肉松弛剂替扎尼定（DS 103-282）和巴氯芬在治疗多发性硬化症所致痉挛方面的抗痉挛效果及耐受性。21名患有稳定痉挛的住院患者参与了为期6周的试验。11名患者接受替扎尼定治疗，10名患者接受巴氯芬治疗，每日剂量逐渐增加。替扎尼定的最佳日剂量在8至36毫克之间，巴氯芬的最佳日剂量在10至80毫克之间。两种药物对整体痉挛状态、痉挛和阵挛的改善相似。相比之下，替扎尼定对肌肉力量、膀胱功能和日常生活活动的改善比巴氯芬更明显。疲劳是替扎尼定最常见的副作用，肌肉无力是巴氯芬最常见的副作用。实验室检查未显示两种药物有任何病理变化。根据这些结果，替扎尼定为痉挛治疗提供了一种新的治疗选择。
